Company to present two oral presentations and four poster presentations
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that new data on Vectra® DA will be featured at the 2014 American College of Rheumatology (ACR) Annual Meeting, Nov. 15-19, 2014, in Boston, Massachusetts. "Vectra DA is a game changer for patients with RA because it provides clinical insights that help inform and improve clinical decisions for patients more effectively than tests like CRP or ESR," said Oscar Segurado, M.D., Chief Medical Officer of Crescendo. "The new clinical data being presented at ACR support the use of Vectra DA to assess RA disease activity and predict patient risk of joint damage."
Oral Presentations
Title: The multi-biomarker disease activity score as a predictor of radiographic progression in a registry of patients with rheumatoid arthritis.
Presenter: Eric H. Sasso
Date: November 19, 2014 9:30 a.m., Room 258 B, Presentation Number 2973
Title: Multi-biomarker disease activity score is associated with power Doppler ultrasound in patients with rheumatoid arthritis in low disease activity state.
Presenter: Nadine Dafranoux
Date:November 19, 2014 9:45 a.m., Room 258 B, Presentation Number 2974
Poster Presentations
Title: Using the multi-biomarker disease activity score as a complementary inclusion criterion for clinical trials in rheumatoid arthritis may enhance recruitment.
Presenter: Ronald F. van Vollenhoven
Date: November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 376
Title: In early rheumatoid arthritis, the multi-biomarker disease activity score at different time-points is predictive of subsequent radiographic progression.
Presenter: Karen Hambardzumyan,
Date: November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 364
Title: In early rheumatoid arthritis patients with non-response to methotrexate monotherapy the change in multi-biomarker disease activity score is differentially associated with subsequent response to non-biological versus biological therapy.
Presenter: Karen Hambardzumyan
Date: November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 367
Title: Preliminary assessment of a multi-biomarker disease activity test for axial spondyloarthritis.
Presenter: Walter P. Maksymowych
Date: November 18, 2014, 9:00-11:00 a.m. Exhibit Hall B, Presentation Number 2615
Gut microbiome changes linked to onset of rheumatoid arthritis among at-risk individuals